骁悉治疗难治性肾病综合征15例近期疗效临床观察

Clinical Investigation of the Efficacy of Mycphenolate Mofetil in Refractory Nephrotic Syndrome

目的：观察麦考酚酸酯（骁悉）治疗难治性肾病综合征的疗效及安全性。方法：选择难治性肾病综合征患者15例,给予骁悉0.5,一日3次,联合激素治疗3个月,减至0.5/d维持治疗观察显效时间,24 h尿蛋白定量、血常规、肾功能、肝功能以及不良反应。结果：用药4~7周时,骁悉显著降低尿蛋白含量,其中蛋白尿完全缓解者7例,显著缓解者4例,部分缓解者3例,无效者1例。治疗过程中2例出现较轻的头痛,1例出现轻度乏力,1例出现轻度的肝酶升高。结论：骁悉对大部分肾病综合征治疗有效,副作用较少,尤其是对肝、肾无毒性反应,使用安全。

Objective：To investigate the mycophenolate mofetil treatment of refractory nephrotic syndrome efficacy,safety.Methods：refractory patients with nephrotic syndrome in 15 cases,given Mycophenolate mofetil 0.5 day three times a joint hormone therapy for three months,to 0.5/d of treatment of effectual time,24 h urinary protein,blood,kidney function,liver function,as well as adverse reactions.Results：4～7 weeks of medication,Mycophenolate mofetil significantly reduce urinary protein content,which proteinuria seven cases of complete remission were significantly alleviate those four cases,partial remission in 3 cases,ineffective in 1 case.During the course of treatment in two cases of lesser headache,one case of a weak,and one patient had mild elevated liver enzymes.Conclusion：Mycophenolate mofetil may be the most effective treatment of nephrotic syndrome,and fewer side effects,particularly on the liver,kidney non-toxic reaction,the use of safety.